Dublin, Sept. 25, 2017 -- The "China Pharmaceutical Distribution Industry Report, 2017-2021" report has been added to Research and Markets' offering.
The Chinese pharmaceutical distribution market has developed steadily but at a slower rate in recent years. The industry rose by 10.4% year on year to RMB1.8393 trillion in 2016 and is expected to hit RMB2.9784 trillion in 2021 at a growth rate of 10% over the next five years driven by favorable policies and downstream demand.
Western medicine sales dominate the Chinese pharmaceutical distribution market, accounting for 74.4% in 2016; East China and Central South China hold relatively higher percentages, up to 61.1% together in 2016.
By the end of Nov 2016, there were 12,975 pharmaceutical wholesalers nationwide which competed fiercely in a lowly concentrated market. Top3 champions seized only a combined 28.7% share of the market in 2016.
As medical reform policies are implemented and consolidation in pharmaceutical wholesale industry accelerates, the Chinese pharmaceutical distribution market will show trends as follows: 1) pharmaceutical E-commerce will become an important model; 2) pharmaceutical supply chain management will be upgraded; 3) capital market will play a bigger role in integration of enterprises; 4) cross-border integration of pharmaceuticals and E-commerce will continue; 5) stiffer competition will improve market concentration; 6) Wholesale-retail integration will spur industry consolidation.
Key Topics Covered:
1. Overview of Pharmaceutical Distribution Industry
1.1 Definition
1.2 Industry Chain
1.3 Strength and Weakness of Pharmaceutical Chain Enterprises
2 Pharmaceutical Distribution Industry in China
2.1 Development Environment
2.1.1 Policy
2.1.2 Economy
2.1.3 Medical Institution
2.1.4 Health Expenditure
2.1.5 Aging
2.1.6 Per Capita Disposable Income
2.2 Status Quo
2.3 Market Size
2.4 Market Structure
2.5 Competitive Landscape
2.6 Development Trends
2.6.1 Pharmaceutical E-commerce Becomes an Important Model
2.6.2 Operating Efficiency and Service Functions Gets Improved Constantly
2.6.3 Capital Market Plays a Bigger Role in Integration of Enterprises
2.6.4 Pharmaceutical Supply-chain Management Services Are Upgraded Rapidly
2.6.5 Cross-border Integration of Pharmaceuticals and E-commerce Continues
2.6.6 Stiffer Competition Improves Market Concentration
2.6.7 Growing Trend towards Regionalization
2.6.8 Wholesale-retail Integration Spurs Industry Consolidation
3 Chinese Drug Retail Market
3.1 Market Size
3.2 Quantity
3.3 Top 100 Pharmacy Chains
3.4 Online Pharmacy
3.5 Independent Pharmacy
4 Major Enterprises
- Cachet Pharmaceutical Co., Ltd.
- Charmacy Pharmaceutical Co., Ltd.
- China Meheco Co., Ltd.
- China National Accord Medicines Corporation Ltd.
- China National Medicines Corporation Ltd.
- China Resources Pharmaceutical Group Limited
- Huadong Medicine Co., Ltd.
- Jointown Pharmaceutical Group Co., Ltd.
- Luyan Pharma Co., Ltd.
- Nanjing Pharmaceutical Co., Ltd.
- Realcan Pharmaceutical Co., Ltd.
- Shanghai No.1 Pharmacy Co., Ltd.
- Shanghai Pharmaceuticals Holding Co., Ltd.
- Zhejiang Int'l Group Co., Ltd.
- Zhejiang Zhenyuan Share Co., Ltd.
For more information about this report visit https://www.researchandmarkets.com/research/gwp2pq/china
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Pharmaceuticals


Eli Lilly and Novo Nordisk Battle for India’s Fast-Growing Obesity Drug Market
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
California Regulator Probes Waymo Robotaxi Stalls During San Francisco Power Outage
DOJ Reaches Settlement With Blackstone’s LivCor Over Alleged Rent Price-Fixing
South Korean Court Clears Korea Zinc’s $7.4 Billion U.S. Smelter Project, Shares Surge
John Carreyrou Sues Major AI Firms Over Alleged Copyrighted Book Use in AI Training
AstraZeneca’s LATIFY Phase III Trial of Ceralasertib Misses Primary Endpoint in Lung Cancer Study
FDA Approves Mitapivat for Anemia in Thalassemia Patients
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
BlackRock-Backed Global Ports Deal Faces Uncertainty Amid Cosco Demands
FTC Praises Instacart for Ending AI Pricing Tests After $60M Settlement
BP Nears $10 Billion Castrol Stake Sale to Stonepeak
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
Nvidia to Acquire Groq in $20 Billion Deal to Boost AI Chip Dominance 



